Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Support on 50 ma need to break over 100 ma. Big run coming
How close were we to have 7s on the board today? Last I seen was 24 mil on 6s
Agreed 100%. This is a great stock to own long term right now. I don't see a reason to have a big run so secure your profits when you can. 23.5% profit is easy. I also can see this running to 7s today. If we get any production news this can run easily to 003-005. Big gains ahead good luck
I did. Just securing profits. Will buy back in another day.
Nice cup and handle on the 3 month chart. I'm in
$LVGI running off .0003 bottom
I'm out this is dropping to far
$LVGI moving up again. Time to get in while 4s can get bought
Smart time to buy.
GEAR was spun off about 16 months ago or so (complete guess) The spun off shares are still worthless as gear is not a publicly traded company. The shares just sit in my brokerage account 0.00. I do remember a pr stating they would continue to do business with LVGI as a seperate company. SLAM is owned by LVGI so I never thought they would do a spin off. Which I believe they stated in a pr they will do a spin off. The CEO has been changed and the information is rather old now. Been trading LVGI for over 2 years.
Looking for a breakout to the 200 ma
Most likely going to increase my position tomorrow.
I'm looking to buy in the .87-90 range. Good luck
I sold my shares. They just wanted more dilution. I took a gamble and lost.
LRDR back on the market. Low float
Back at it
Easy 1.50
Only 88 shareholders. When it does open back im sure some buying will happen so hold on to those shares for nice gains to come.
My shares have been switched to the right amount so I'm sure they are getting ready to open back up or give a pr on a merger agreement.
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 000-54577
Laredo Resources Corp.
(Exact name of registrant as specified in its charter)
HOUSTON, Nov. 24, 2014 /PRNewswire/ -- Hercules Offshore, Inc. (Nasdaq: HERO) announced today that the Company will present at the following investor conferences:
Cowen's 4th Annual Ultimate Energy Conference in New York on Tuesday, December 2, 2014, at 11:30 a.m. EST (10:30 a.m. CST).
Great fast moving plays today. Lots of volume. Just what I enjoy
Big things happening
We were also promised slam to be out by July 4th. When promises are broken it's not easy to trust.
Ummmm.... Average down? It might be awhile before you see those prices.
I actually don't think this is going for another big run like last time. I do believe that was a pre loaded pump and dump. I just got lucky and averaged down prior to the big run. I do have a small position now and I don't expect much action for atleast another month or 2. I do believe lvgi has a lot of good things happening and I will average down and hold for more gains.
This pos made me $27,000 this year!!! I hope it drops lower so I can buy more.
And that's exactly what I was assuming.
Any type of pr would be good. I have made a lot on this ticker but I do not trust it until I see a press release.
Long term buy short term sell. I play swings and dips a lot. It matched the previous low today which caused the buying frenzy. If tomorrow makes a new high then it changes the trends. Breaking 8 is what I'm waiting to see. And I'm waiting for a 6.6 support. Would still be making higher lows. That's why long term is a buy.
Looking for 6.65
Should dump coming soon
Get Alerts GWPH Hot Sheet
Price: $73.75 +4.67%
Overall Analyst Rating:
BUY (Up Up)
Revenue Growth %: +17.8%
GW Pharmaceuticals plc (Nasdaq: GWPH) today announced it has commenced a Phase 2/3 clinical trial of Epidiolex® (cannabidiol or CBD) for the treatment of Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy.
"The results of our open-label trial of Epidiolex in children with Dravet syndrome have been very encouraging and we are excited to begin this important placebo-controlled clinical trial," stated Orrin Devinsky MD, Professor of Neurology, Neurosurgery, and Psychiatry at NYU School of Medicine, and Principal Investigator of the trial.
"As one of the largest epilepsy centers in the country, our focus has always been to find new and innovative ways to treat and cure children with various forms of epilepsy," said Dr. Angus Wilfong, neurologist at Texas Children's Hospital. "Initial trials of Epidiolex have shown promising signals of efficacy in children with treatment- resistant epilepsy, and we are pleased to have the opportunity to partner with GW Pharmaceuticals in the first worldwide trial for this group of patients with such a catastrophic form of epilepsy," he continued.
"We are pleased to have advanced Epidiolex into the pivotal stage of clinical development. The start of this Phase 2/3 trial represents a significant milestone for children that suffer with Dravet syndrome for which there remains a substantial unmet medical need," stated Justin Gover, GW's Chief Executive Officer. "Epidiolex is the first plant-based CBD medicine to be studied in a FDA-authorized, placebo-controlled trial and we look forward to working with leading pediatric epilepsy centers across the U.S. to advance this clinical program as rapidly as possible."
The Phase 2/3 trial is a two-part randomized double-blind, placebo-controlled parallel group safety, tolerability, pharmacokinetic and efficacy trial of single and multiple doses of Epidiolex to treat Dravet syndrome in children who are being treated with other anti-epileptic drugs. Part one comprises the pharmacokinetic and dose-finding elements of the trial in a total of 30 patients over a three week treatment period. Part two is a placebo-controlled safety and efficacy evaluation of Epidiolex over a three month treatment period in a total of 80 patients. All patients who complete the study will be eligible to receive Epidiolex under a long term open label extension study.
GW anticipates commencing an additional Phase 3 trial in Dravet syndrome in the first quarter of 2015 in parallel with part two of the first Phase 2/3 trial. The company also expects to commence two Phase 3 clinical trials in Lennox-Gastaut syndrome in the first quarter of 2015.
To obtain information about this clinical trial or eligibility criteria the treating physician should contact:medicaldirector@gwpharm.com
I have been wrong before. 34 resistance was tested and failed a few times today. It gets me worried that we don't have enough buyers at these levels. 26 might see a test again
Not looking good. Positive market day and this is going for new lows of the day.
Begins phase 2/3 on epidiolex trials!!!
That's what a spin off is.
I don't care for spinoffs. Your shares are only worth money when the company goes public. Takes forever
Can someone post the short % that was on Friday. I wanna see how much of a squeeze we get
Congrats to everyone holding shares. It's been a long wait.